Sanjana Srinivasan

Sanjana Srinivasan

Auto-generated profile, based on publicly available information

Sanjana Srinivasan

The University of Texas MD Anderson Cancer Center 4 Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division Houston, Texas

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2017 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
MRMichael C Robertson
Michael C Robertson
ETEdward Tsai
Edward Tsai
ELElizabeth J Lyons
Elizabeth J Lyons
SSSanjana Srinivasan
Sanjana Srinivasan
MSMaria Swartz
Maria Swartz
KBKaren M. Basen-Engquist
Karen M. Basen-Engquist
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

13 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HLHey Min Lee
Hey Min Lee
ASAjay Kumar. Saw
Ajay Kumar. Saw
VMVan K Morris
Van K Morris
Stefania NapolitanoStefania Napolitano
Stefania Napolitano
CBChristopher Bristow
Christopher Bristow
KRKunal Rai
Kunal Rai
Purpose: BRAFV600E-mutated colorectal cancer exhibits a strong correlation with DNA hypermethylation, suggesting that this subgroup of tumors presents unique epigenomic phenotypes. Nonetheless, 5-azacitidine, which inhibits DNA methyltransferase activity, is not efficacious in BRAFV600E colorectal cancer in vivo. Experimental Design: We randomized and treated mice implanted with patient-derived tumor xenografts harboring BRAFV600E mutation with control, 5-azacitidine, vemurafenib (BRAF inhibitor), or the combination. Comprehensive epigenomic profiling was conducted on control and 5-azacitidine–treated tumor samples, including DNA methylation, histone modifications, chromatin accessibility, and gene expression. Combinations of epigenetic agents were explored in preclinical BRAFV600E colorectal cancer models. Results: A profound reduction of DNA methylation levels upon 5-azacitidine treatment was confirmed, however, transcriptional repression was not relieved. This study unbiasedly explored the adaptive engagement of other epigenomic modifications upon 5-azacitidine treatment. A loss of histone acetylation and a gain of histone methylations, including H3K27 and H3K4 trimethylation, were observed around these hypomethylated regions, suggesting the involvement of polycomb repressive complex (PRC) activity around the genome with loss of DNA methylation, therefore maintaining the repression of key tumor-suppressor genes. Combined inhibition of PRC activity through EZH2 inhibition with 5-azacitidine treatment additively improved efficacies in BRAFV600E colorectal cancer cells. Conclusions: In conclusion, DNA hypomethylation by 5-azacitidine exhibits a close association with H3K27me3 and PRC activity in BRAFV600E colorectal cancer, and simultaneous blockade of DNA methyltransferase and EZH2 holds promise as a potential therapeutic strategy for patients with BRAFV600E-mutated colorectal cancer.

21 February 2025 in Science Advances
Verified
Journal Article
Open access
RBRecep Bayraktar
Recep Bayraktar
YTYitao Tang
Yitao Tang
MDMihnea Dragomir
Mihnea Dragomir
CICristina Ivan
Cristina Ivan
XPXinxin Peng
Xinxin Peng
George CalinGeorge Calin
George Calin
The mutational landscape of phylogenetically ultraconserved elements (UCEs), especially those in noncoding DNAs (ncUCEs), and their functional relevance in cancers remain poorly characterized. Here, we perform a systematic analysis of whole-genome and in-house targeted UCE sequencing datasets from more than 3000 patients with cancer of 13,736 UCEs and demonstrate that ncUCE somatic alterations are common. Using a multiplexed CRISPR knockout screen in colorectal cancer cells, we show that the loss of several altered ncUCEs significantly affects cell proliferation. In-depth functional studies in vitro and in vivo further reveal that specific ncUCEs can be enhancers of tumor suppressors (such as ARID1B) and silencers of oncogenic proteins (such as RPS13). Moreover, several miRNAs located in ncUCEs are recurrently mutated. Mutations in miR-142 locus can affect the Drosha-mediated processing of precursor miRNAs, resulting in the down-regulation of the mature transcript. These results provide systematic evidence that specific ncUCEs play diverse regulatory roles in cancer.

16 June 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
HLHey Min Lee
Hey Min Lee
ZZZhao Zheng
Zhao Zheng
ASAlexey Sorokin
Alexey Sorokin
CWChi Wut Wong
Chi Wut Wong
Stefania NapolitanoStefania Napolitano
Stefania Napolitano
SKScott Kopetz
Scott Kopetz
Purpose: Aberrant enhancer dynamics play a critical role in the initiation and progression of colorectal cancer, particularly in the BRAFV600E-mutated metastatic subtype, which uniquely exhibits a strong epigenetic phenotype. Building on this epigenetic vulnerability, bromodomain 2, a reader of H3K27ac-marked enhancers, was found to be synthetically lethal with BRAF + EGFR inhibition. Experimental Design: We evaluated the effectiveness of targeting aberrant enhancers with bromodomain and extraterminal (BET) + MAPK pathway inhibitors in patient-derived xenograft models of metastatic colorectal cancer, followed by comprehensive transcriptomic and chromatin profiling. Results: BET plus standard MAPK inhibitors demonstrated improved efficacy against BRAFV600E colorectal cancer and selective improvements against RAS-mutant colorectal cancer in vivo. This combination induced a more profound downregulation of the MAPK signaling pathway than MAPK inhibition alone. The loss of activation signals on H3K27ac-marked enhancers led to the dysregulation of core regulatory circuitries, especially the MAPK downstream E26 transformation–specific transcription factor (TF) family and MYC. Single-nucleus RNA sequencing + Assay for Transposase-Accessible Chromatin using sequencing distinguished differential transcriptomic and chromatin dynamics at the cell-type level. Profound downregulation of well-differentiated cell types confirmed deep inhibition of MAPK signaling and downstream TF. Conversely, an abundance of dedifferentiated cell populations emerged after MAPK or combination inhibition, suggesting therapy-induced cell-state switching and adaptation. Conclusions: Our work demonstrates that BET inhibition improves MAPK signaling blockade through profound epigenetic reprogramming of core TF circuits. These findings provide a preclinical rationale for the evaluation of BET + BRAF + EGFR inhibition in patients with treatment-refractory BRAFV600E metastatic colorectal cancer (NCT06102902).

2 December 2025 in Cancer Research
Verified
Journal Article
Open access
ZCZiheng Chen
Ziheng Chen
IHI-Lin Ho
I-Lin Ho
JLJintan Liu
Jintan Liu
MSMelinda Soeung
Melinda Soeung
EYEr-Yen Yen
Er-Yen Yen
GDGiulio Draetta
Giulio Draetta
Both metabolic dysregulation and the immunosuppressive tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) contribute to the recalcitrance of this lethal disease to treatment. Accordingly, we aimed to identify and characterize a target that elicits an anticancer response through both disrupting cancer cell redox homeostasis and increasing the immunogenicity of PDAC. First, mitochondrial metabolic dependencies in PDAC were identified by using a CRISPR-Cas9 screening system with a custom single-guide RNA library. Functional validation analyses revealed GFER, a mitochondrial FAD-dependent sulfhydryl oxidase, as an essential regulator of tumor growth. In vitro and in vivo methodologies demonstrated that GFER depletion perturbed redox homeostasis and stimulated tumor immunogenicity, including sensitization to immune checkpoint blockade. In patient-derived xenograft models of PDAC, the growth-inhibitory response induced by GFER depletion was mediated by an altered oxidative balance that released damaged mitochondrial DNA into the cytoplasm of tumor cells, leading to the activation of the cGAS-STING pathway and expression of type I IFNs. This effect was recapitulated in a mouse immunocompetent syngeneic PDAC model, in which GFER depletion suppressed tumor growth and promoted T-cell infiltration to enhance tumor-killing effects. Consequently, GFER depletion significantly increased the antitumor efficacy of immune checkpoint blockade. Overall, these findings identify GFER as a critical node for both mitochondrial redox homeostasis and immunomodulation in PDAC and reveal a therapeutic opportunity for sensitizing PDAC to immune checkpoint blockade. Significance: GFER is essential for mitochondrial redox balance and suppressing tumor immunogenicity in pancreatic tumors, with the combination of GFER inhibition with immune checkpoint blockade resulting in a strong antitumor response.

24 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
FCFrancesca Citron
Francesca Citron
IHI-Lin Ho
I-Lin Ho
CBChiara Balestrieri
Chiara Balestrieri
ZLZhaoliang Liu
Zhaoliang Liu
EYEr-Yen Yen
Er-Yen Yen
GDGiulio Draetta
Giulio Draetta
It is unclear how cells counteract the potentially harmful effects of uncoordinated DNA replication in the context of oncogenic stress. Here, we identify the WRAD (WDR5/RBBP5/ASH2L/DPY30) core as a modulator of DNA replication in pancreatic ductal adenocarcinoma (PDAC) models. Molecular analyses demonstrated that the WRAD core interacts with the replisome complex, with disruption of DPY30 resulting in DNA re-replication, DNA damage, and chromosomal instability (CIN) without affecting cancer cell proliferation. Consequently, in immunocompetent models, DPY30 loss induced T cell infiltration and immune-mediated clearance of highly proliferating cancer cells with complex karyotypes, thus improving anti-tumor efficacy upon anti-PD-1 treatment. In PDAC patients, DPY30 expression was associated with high tumor grade, worse prognosis, and limited response to immune checkpoint blockade. Together, our findings indicate that the WRAD core sustains genome stability and suggest that low intratumor DPY30 levels may identify PDAC patients who will benefit from immune checkpoint inhibitors.